Tenecteplase
ST Elevation Myocardial Infarction
AO GENERIUMprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the ST Elevation Myocardial Infarction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ticagrelor AstraZeneca | Phase 4 | BB |
Plavix IHF GmbH - Institut für Herzinfarktforschung | Phase 4 | BB |
Acetylsalicylic Acid St. Antonius Hospital | Phase 4 | BB |
Dabigatran IHF GmbH - Institut für Herzinfarktforschung | Phase 4 | BB |
Rivaroxaban IHF GmbH - Institut für Herzinfarktforschung | Phase 4 | BB |
Gnr-060 AO GENERIUM | Phase 3 | B |
Alirocumab Population Health Research Institute | Phase 2 | B |
Same molecule, other indications
Tenecteplase is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →